FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3183205402> ?p ?o ?g. }

• W3183205402 endingPage "405" @default.
• W3183205402 startingPage "395" @default.
• W3183205402 abstract "For postmenopausal women with hormone-receptor-positive breast cancer, the most effective duration for adjuvant therapy with an aromatase inhibitor remains unclear.In this prospective, phase 3 trial, we randomly assigned postmenopausal women with hormone-receptor-positive breast cancer who had received 5 years of adjuvant endocrine therapy to receive the aromatase inhibitor anastrozole for an additional 2 years (2-year group, receiving a total of 7 years) or an additional 5 years (5-year group, receiving a total of 10 years). The primary end point was disease-free survival. The primary analysis included all the patients who were still participating in the trial and who had no recurrence 2 years after randomization (i.e., when treatment in the 2-year group had ended). Secondary end points were overall survival, contralateral breast cancer, second primary cancer, and clinical bone fracture.Among the 3484 women who were enrolled in the trial, 3208 remained in the trial without disease progression after the first 2 years of extended anastrozole treatment following randomization. Among these women, disease progression or death occurred in 335 women in each treatment group in the primary-analysis set at 8 years (hazard ratio, 0.99; 95% confidence interval [CI], 0.85 to 1.15; P = 0.90). No between-group differences occurred in most secondary end points, and subgroup analyses did not indicate differences in any particular subgroup. The risk of clinical bone fracture was higher in the 5-year group than in the 2-year group (hazard ratio, 1.35; 95% CI, 1.00 to 1.84).In postmenopausal women with hormone-receptor-positive breast cancer who had received 5 years of adjuvant endocrine therapy, extending hormone therapy by 5 years provided no benefit over a 2-year extension but was associated with a greater risk of bone fracture. (Funded by AstraZeneca and the Austrian Breast and Colorectal Cancer Study Group; ABCSG-16/SALSA ClinicalTrials.gov number, NCT00295620.)." @default.
• W3183205402 created "2021-08-02" @default.
• W3183205402 creator A5001523609 @default.
• W3183205402 creator A5013406094 @default.
• W3183205402 creator A5015052494 @default.
• W3183205402 creator A5018732880 @default.
• W3183205402 creator A5019454470 @default.
• W3183205402 creator A5022097827 @default.
• W3183205402 creator A5025718393 @default.
• W3183205402 creator A5025804272 @default.
• W3183205402 creator A5034508175 @default.
• W3183205402 creator A5036026407 @default.
• W3183205402 creator A5036695602 @default.
• W3183205402 creator A5038898280 @default.
• W3183205402 creator A5038918684 @default.
• W3183205402 creator A5039097727 @default.
• W3183205402 creator A5039285562 @default.
• W3183205402 creator A5039886032 @default.
• W3183205402 creator A5039994927 @default.
• W3183205402 creator A5040658545 @default.
• W3183205402 creator A5041466806 @default.
• W3183205402 creator A5042756447 @default.
• W3183205402 creator A5045803325 @default.
• W3183205402 creator A5057389495 @default.
• W3183205402 creator A5068091207 @default.
• W3183205402 creator A5075260634 @default.
• W3183205402 creator A5080544752 @default.
• W3183205402 creator A5082012725 @default.
• W3183205402 creator A5082285486 @default.
• W3183205402 creator A5082631402 @default.
• W3183205402 creator A5086400759 @default.
• W3183205402 date "2021-07-29" @default.
• W3183205402 modified "2023-10-12" @default.
• W3183205402 title "Duration of Adjuvant Aromatase-Inhibitor Therapy in Postmenopausal Breast Cancer" @default.
• W3183205402 cites W1982900907 @default.
• W3183205402 cites W2000366267 @default.
• W3183205402 cites W2101848871 @default.
• W3183205402 cites W2101881391 @default.
• W3183205402 cites W2122786185 @default.
• W3183205402 cites W2127714324 @default.
• W3183205402 cites W2131398863 @default.
• W3183205402 cites W2145777628 @default.
• W3183205402 cites W2148096512 @default.
• W3183205402 cites W2148378495 @default.
• W3183205402 cites W2150962478 @default.
• W3183205402 cites W2169440122 @default.
• W3183205402 cites W2214665719 @default.
• W3183205402 cites W2409054761 @default.
• W3183205402 cites W2581784699 @default.
• W3183205402 cites W2727617588 @default.
• W3183205402 cites W2742723442 @default.
• W3183205402 cites W2745775556 @default.
• W3183205402 cites W2761190519 @default.
• W3183205402 cites W2767009332 @default.
• W3183205402 cites W2767600184 @default.
• W3183205402 cites W2787553551 @default.
• W3183205402 cites W2788523770 @default.
• W3183205402 cites W2791535250 @default.
• W3183205402 cites W2892456672 @default.
• W3183205402 cites W2902603078 @default.
• W3183205402 cites W2902844274 @default.
• W3183205402 cites W2903279335 @default.
• W3183205402 cites W2961237381 @default.
• W3183205402 cites W2965857754 @default.
• W3183205402 cites W2998985226 @default.
• W3183205402 cites W3016358164 @default.
• W3183205402 cites W3044807921 @default.
• W3183205402 cites W3048724813 @default.
• W3183205402 cites W3048934302 @default.
• W3183205402 cites W3086811558 @default.
• W3183205402 cites W3091091275 @default.
• W3183205402 cites W3095485902 @default.
• W3183205402 cites W3116128628 @default.
• W3183205402 cites W3169782298 @default.
• W3183205402 doi "https://doi.org/10.1056/nejmoa2104162" @default.
• W3183205402 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34320285" @default.
• W3183205402 hasPublicationYear "2021" @default.
• W3183205402 type Work @default.
• W3183205402 sameAs 3183205402 @default.
• W3183205402 citedByCount "63" @default.
• W3183205402 countsByYear W31832054022021 @default.
• W3183205402 countsByYear W31832054022022 @default.
• W3183205402 countsByYear W31832054022023 @default.
• W3183205402 crossrefType "journal-article" @default.
• W3183205402 hasAuthorship W3183205402A5001523609 @default.
• W3183205402 hasAuthorship W3183205402A5013406094 @default.
• W3183205402 hasAuthorship W3183205402A5015052494 @default.
• W3183205402 hasAuthorship W3183205402A5018732880 @default.
• W3183205402 hasAuthorship W3183205402A5019454470 @default.
• W3183205402 hasAuthorship W3183205402A5022097827 @default.
• W3183205402 hasAuthorship W3183205402A5025718393 @default.
• W3183205402 hasAuthorship W3183205402A5025804272 @default.
• W3183205402 hasAuthorship W3183205402A5034508175 @default.
• W3183205402 hasAuthorship W3183205402A5036026407 @default.
• W3183205402 hasAuthorship W3183205402A5036695602 @default.
• W3183205402 hasAuthorship W3183205402A5038898280 @default.
• W3183205402 hasAuthorship W3183205402A5038918684 @default.
• W3183205402 hasAuthorship W3183205402A5039097727 @default.

• next